Recce Pharmaceuticals Ltd
ASX:RCE

Watchlist Manager
Recce Pharmaceuticals Ltd Logo
Recce Pharmaceuticals Ltd
ASX:RCE
Watchlist
Price: 0.33 AUD 3.13% Market Closed
Market Cap: 86.5m AUD

Relative Value

The Relative Value of one RCE stock under the Base Case scenario is 0.05 AUD. Compared to the current market price of 0.33 AUD, Recce Pharmaceuticals Ltd is Overvalued by 86%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RCE Relative Value
Base Case
0.05 AUD
Overvaluation 86%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
95
vs Industry
16
Median 3Y
25.7
Median 5Y
53.6
Industry
2.5
Forward
8.2
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-15.3
Industry
21.6
Forward
-4.7
vs History
vs Industry
17
Median 3Y
-19.8
Median 5Y
-33
Industry
16.7
vs History
vs Industry
13
Median 3Y
-11.9
Median 5Y
-19.4
Industry
24
vs History
vs Industry
0
Median 3Y
-12.1
Median 5Y
12.7
Industry
2.2
vs History
95
vs Industry
15
Median 3Y
25.4
Median 5Y
52.5
Industry
2.7
Forward
8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.3
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-14.2
Industry
12.9
Forward
-5.9
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-14.2
Industry
16.3
Forward
-5.6
vs History
vs Industry
19
Median 3Y
-18.5
Median 5Y
-30.2
Industry
15.2
vs History
vs Industry
17
Median 3Y
-18.4
Median 5Y
-29.9
Industry
17.7
vs History
vs Industry
0
Median 3Y
-51.1
Median 5Y
390.3
Industry
1.9

Multiples Across Competitors

RCE Competitors Multiples
Recce Pharmaceuticals Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Recce Pharmaceuticals Ltd
ASX:RCE
86.5m AUD 8.8 -4.8 -5.1 -5.1
US
Eli Lilly and Co
NYSE:LLY
757.6B USD 15.5 68.2 36.6 40
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
377.3B USD 4.2 17.3 12.6 16.6
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.5 18.8 13 14.9
CH
Roche Holding AG
SIX:ROG
205B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
188.9B CHF 4.4 18.4 10.8 14.5
UK
AstraZeneca PLC
LSE:AZN
165.3B GBP 4 28.6 130.9 197.4
US
Merck & Co Inc
NYSE:MRK
210.5B USD 3.3 12.1 8.9 10.9
IE
Endo International PLC
LSE:0Y5F
184.8B USD 79.7 -63.2 294 737.3
US
Pfizer Inc
NYSE:PFE
144.1B USD 2.3 18.3 7.8 10.9
P/E Multiple
Earnings Growth PEG
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average P/E: 25.8
Negative Multiple: -4.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
68.2
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.3
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.8
18%
1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.6
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12.1
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -63.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.3
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average EV/EBITDA: 437
Negative Multiple: -5.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.6
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13
13%
1
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.9
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.9
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
294
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average EV/EBIT: 1 875.6
Negative Multiple: -5.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.6
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.9
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14.5
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.4
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.9
11%
1
IE
E
Endo International PLC
LSE:0Y5F
737.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1